What are the drug interactions and precautions associated with midodrine?

Midodrine Drug Interactions and Precautions

Avoid combining midodrine with MAO inhibitors, linezolid, and other vasoconstrictors (phenylephrine, pseudoephedrine, ephedrine, dihydroergotamine, thyroid hormones, droxidopa), as these significantly increase the risk of dangerous hypertension. 1

Critical Drug Interactions

Absolute Contraindications

• MAO inhibitors and linezolid: Avoid concurrent use entirely 1
• Other vasoconstrictors: Including phenylephrine, pseudoephedrine, ephedrine, dihydroergotamine, thyroid hormones, and droxidopa increase hypertension risk. If unavoidable, monitor blood pressure closely 1

Cardiac Medications Requiring Caution

• Cardiac glycosides (digitalis): Can precipitate bradycardia, AV block, or arrhythmias when combined with midodrine 1
• Beta-blockers: Exercise caution as both agents can reduce heart rate. Monitor for bradycardia symptoms (pulse slowing, increased dizziness, syncope, cardiac awareness) 1
• Psychopharmacologic agents: Use cautiously with any drugs that directly or indirectly reduce heart rate 1

Alpha-Adrenergic Antagonists

• Alpha-blockers (prazosin, terazosin, doxazosin): These directly antagonize midodrine's effects and should be avoided 1

Fludrocortisone Combination

• Salt-retaining steroids (fludrocortisone): Midodrine can be used with fludrocortisone, but supine hypertension risk increases substantially. Consider reducing fludrocortisone dose or decreasing salt intake before starting midodrine 1

Potential Renal Tubular Interactions

Midodrine's active metabolite (desglymidodrine) may interact with drugs sharing the same renal tubular secretion pathway, including:

• Metformin
• Cimetidine, ranitidine
• Procainamide
• Triamterene
• Flecainide
• Quinidine

While no experimental evidence confirms these interactions, monitor closely when combining 1

Critical Precautions by Patient Population

Supine Hypertension (Most Important)

• Primary concern: Up to 25% of patients develop supine hypertension 2
• Management: Take last daily dose 3-4 hours before bedtime; sleep with head of bed elevated 1
• Warning symptoms: Cardiac awareness, pounding in ears, headache, blurred vision—discontinue immediately if these persist 1

Renal Impairment

• Start at reduced dose of 2.5 mg due to renal elimination of active metabolite
• Assess renal function before initiating therapy 1

Hepatic Impairment

• Use with caution as liver metabolizes midodrine
• Assess hepatic function before starting 1

Urinary Retention

• High-risk population: Older males and patients with spinal cord injury
• Midodrine acts on alpha-adrenergic receptors of bladder neck, causing urinary retention 1
• Spinal cord injury patients: May develop insidious urologic complications including hydroureteronephrosis and worsening detrusor-sphincter dyssynergia. Consider intermittent catheterization with antimuscarinic therapy if midodrine is essential 3

Diabetic Patients

• Use cautiously, especially when combined with fludrocortisone 1

Visual Problems/Glaucoma

• Exercise caution when combining with fludrocortisone, which increases intraocular pressure 1

Over-the-Counter Medication Warning

Patients must be counseled to avoid OTC cold remedies and diet aids containing sympathomimetics (phenylephrine, pseudoephedrine, ephedrine), as these potentiate midodrine's pressor effects and can cause dangerous hypertension 1

Monitoring Requirements

• Blood pressure: Monitor carefully for supine hypertension, especially when combining with other vasoconstrictors or fludrocortisone 1
• Heart rate: Watch for bradycardia, particularly with cardiac glycosides or beta-blockers 1
• Renal and hepatic function: Assess before initiation and periodically thereafter 1

Common Pitfalls to Avoid

1. Timing error: Patients taking midodrine too close to bedtime develop supine hypertension—enforce the 3-4 hour rule
2. Polypharmacy oversight: Missing OTC sympathomimetics in medication reconciliation
3. Urologic complications in spinal cord injury: These develop insidiously; maintain high suspicion 3
4. Dose-dependent mortality risk: Recent data suggests higher doses may increase mortality in hemodialysis patients, though this requires validation 4